Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10878741 | 0.83 | GAA (0.43) | GAACA9CA12CA1CA2 | |
| SCHEMBL11207535 | 0.83 | GAA (0.54) | GAACA9CA12CA1CA2 | |
| SCHEMBL1357746 | 0.80 | GAA (0.50) | GAACA9CA12CA1CA2 | |
| SCHEMBL19372613 | 0.79 | GAA (0.54) | GAACA9CA12CA1CA2 | |
| SCHEMBL10566216 | 0.78 | CA2 (0.50) | CA9CA12CA1CA2CA4 | |
| SCHEMBL1000354 | 0.78 | GAA (0.58) | GAACA9CA12CA1CA2 | |
| SCHEMBL30232517 | 0.78 | CA2 (0.50) | CA9CA12CA1CA2CA4 | |
| SCHEMBL8356100 | 0.76 | GAA (0.46) | GAACA9CA12CA1CA2 | |
| SCHEMBL7724493 | 0.76 | GAA (0.46) | GAACA9CA12CA1CA2 | |
| SCHEMBL6097627 | 0.76 | LMNA (0.42) | SMN1; SMN2ADRA2AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | claimed |
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| CN-106083670-A | The synthetic method of cancer therapy drug Ceritinib intermediate 1 amino 2 (isopropyl sulphonyl) benzene | 常州安迪沃克医药科技有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-20130338358-A1 | METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND AND SYNTHETIC INTERMEDIATE THEREFOR | ASTELLAS PHARMA INC. (JP) | 2013-12-19 | — | — | US | claimed |
| EP-2669281-A1 | METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND, AND SYNTHETIC INTERMEDIATE THEREFOR | Astellas Pharma Inc. (JP) | 2013-12-04 | — | — | EP | claimed |
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| CN-119930602-A | Pyrimidine ring-containing 2, 5-disubstituted thiadiazole compound, and preparation method and application thereof | 山东第二医科大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-101535276-A | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338358-A1 | METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND AND SYNTHETIC INTERMEDIATE THEREFOR | EML4, ALK, MET | GAA 3085/4885CA9 4065/4885CA12 4667/4885 |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | GAA 2745/4885CA9 813/4885CA12 2407/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | GAA 3538/4885CA9 1403/4885CA12 2894/4885 |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | GAA 1754/4885CA9 4523/4885CA12 4851/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | GAA 1344/4885CA9 10/4885CA12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.